Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple SclerosisStephen L. Hauser, Ludwig Kappos, Amit Bar‐Or et al.|New England Journal of Medicine|2016Cited by 2k
Ocrelizumab versus Placebo in Primary Progressive Multiple SclerosisXavier Montalbán, Jerry S. Wolinsky, Stephen L. Hauser et al.|New England Journal of Medicine|2016Cited by 1.9k
How patients with multiple sclerosis acquire disabilityFred Lublin, Robert A Bermel, Dieter A. Häring et al.|Brain|2022Cited by 532
metabolic recovery after exercise and the assessment of mitochondrial function <i>in Vivo</i> in human skeletal muscle by means of <sup>31</sup>P NMRDouglas L. Arnold, G. K. Radda, Paul M. Matthews|Magnetic Resonance in Medicine|1984Cited by 441
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple SclerosisXavier Montalbán, Jerry S. Wolinsky, Douglas L. Arnold et al.|New England Journal of Medicine|2019Cited by 320